J Cancer
2017; 8(3):410-416.
doi:10.7150/jca.17144 This issueCite
Review
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Liting Guo, Haijun Zhang, Baoan Chen✉
Department of Hematology and Oncology (Key Department of Jiangsu Medicine), The Affiliated Zhongda Hospital, Medical School of Southeast University, Nanjing.
✉ Corresponding author: Baoan Chen. Department of Hematology and Oncology (Key Department of Jiangsu Medicine), The Affiliated Zhongda Hospital, Medical School of Southeast University, Dingjiaqiao 87, Gulou District, Nanjing 210009, Jiangsu Province, People's Republic of China. Tel +86 25 8327 2006 Fax +86 25 8327 2011 Email cba8888com.More
Citation:
Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer 2017; 8(3):410-416. doi:10.7150/jca.17144. https://www.jcancer.org/v08p0410.htm
Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers. The present review summarizes the efficacy and current status of clinical trials of nivolumab and that enabled nivolumab to be investigated in patients.
Guo, L., Zhang, H., Chen, B. (2017). Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. Journal of Cancer, 8(3), 410-416. https://doi.org/10.7150/jca.17144.
ACS
Guo, L.; Zhang, H.; Chen, B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J. Cancer 2017, 8 (3), 410-416. DOI: 10.7150/jca.17144.
NLM
Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer 2017; 8(3):410-416. doi:10.7150/jca.17144. https://www.jcancer.org/v08p0410.htm
CSE
Guo L, Zhang H, Chen B. 2017. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer. 8(3):410-416.